Doravirine

多拉韦林

Report date: 2025/07/17 17:48:18
NME

Base Information

Drug NameDoravirine
Drug Alias Name多雷韦林doravirinadoravirinumPifeltroMK-1439 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNon-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptase
Therapy Area/IndicationsParturitionLipid Metabolism DisordersCardiovascular Diseases +[6] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2018/08/30
Country/TerritoryUnited StatesThailandMexico +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterMerck Sharp & Dohme BvMerck & Co Inc +[6] 
Inactive CompaniesN/A
Active IndicationsParturitionLipid Metabolism DisordersCardiovascular Diseases +[5] 
Inactive IndicationsRenal Insufficiency

Other Information

ATC CodeJ05AG06
Related LinksWikipediaKEGG